Aclarion, Inc. is a healthcare technology company that employs magnetic resonance spectroscopy (MRS) and, and a biomarker to optimize clinical treatments. The Company’s signal processing software and expert system transform raw spectral MRS data into clear metabolic biomarkers to help physicians determine between painful and nonpainful discs of the lumbar spine. The Company is using augmented intelligence in a post-processing algorithm to analyze and quantifies the biomarker data, generating ratio metrics for each lumbar disc that are individualized to a normative data set. The Company’s technology is focused on the care of patients suffering from chronic low back pain.
No insider trading activity.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.